TransCode Therapeutics (RNAZ) Launches Phase 2a Trial for Colorectal Cancer Drug TTX-MC138
TransCode Therapeutics (RNAZ) filed an 8-K on Dec 11, 2025, announcing a Phase 2a dose-expansion trial for TTX-MC138 in colorectal cancer with minimal residual disease.